載入中
DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, DexCom, Inc. has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Ireland Limited to advance blood-based or interstitial glucose monitoring products. The company directly sells its offerings to specialists such as endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and maintains its headquarters in San Diego, California.
收盤時
US$85.92
+US$1.81 · +2.15%
盤後
US$85.5001
−US$0.4199 · -0.49%
10月12日 下午6:22 ET
盤中時間採用ET。市場資料可能有所延遲。
DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, DexCom, Inc. has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Ireland Limited to advance blood-based or interstitial glucose monitoring products. The company directly sells its offerings to specialists such as endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and maintains its headquarters in San Diego, California.
日內區間
目前US$85.92
52週區間
目前US$85.92
盤中時間採用ET。市場資料可能有所延遲。
DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, DexCom, Inc. has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Ireland Limited to advance blood-based or interstitial glucose monitoring products. The company directly sells its offerings to specialists such as endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and maintains its headquarters in San Diego, California.
日內區間
目前US$85.92
52週區間
目前US$85.92
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 46.62億 USD | 40.33億 USD | 36.22億 USD | 29.1億 USD | 24.49億 USD |
| 銷貨成本 | 18.6億 USD | 15.95億 USD | 13.33億 USD | 10.27億 USD | 7.68億 USD |
| 毛利 | 28.02億 USD | 24.38億 USD | 22.89億 USD | 18.83億 USD | 16.81億 USD |
| 研究與開發 | 5.99億 USD | 5.52億 USD | 5.06億 USD | 4.84億 USD | 6.04億 USD |
| 銷售、一般及管理費用 | 12.91億 USD | 12.86億 USD | 11.85億 USD | 10.08億 USD | 8.11億 USD |
| 營業費用 | 18.9億 USD | 18.38億 USD | 16.91億 USD | 14.92億 USD | 14.15億 USD |
| 利息收入 | 1.13億 USD | 1.34億 USD | 1.35億 USD | 2380萬 USD | 170萬 USD |
| 利息支出 | 1830萬 USD | 1900萬 USD | 2030萬 USD | 1860萬 USD | 1880萬 USD |
| 折舊和攤銷 | 2.52億 USD | 2.18億 USD | 1.86億 USD | 1.56億 USD | 1.02億 USD |
| 營業利益 | 9.12億 USD | 6億 USD | 5.98億 USD | 3.91億 USD | 2.66億 USD |
| 淨利 | 8.36億 USD | 5.76億 USD | 5.42億 USD | 3.41億 USD | 2.17億 USD |
公司資料更新於 2026年10月12日。
已公布業績及可用的市場共識預估。
已公布業績及可用的市場共識預估。
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$95.07
上漲空間 10.65%報告持有此股票曝險的交易所交易基金。
State Street SPDR S&P 500 ETF1557.T608.95億0.05%129.43兆 JPY0.09%¥122,850+0.12%
Vanguard Morningstar Total Stock Market ETFVTI11.17億0.05%2.3兆 USD0.03%US$381.57-0.10%
Vanguard S&P 500 ETFVOO9.34億0.05%1.8兆 USD0.03%US$715.13-0.06%
Vanguard Morningstar Mid-Cap ETFVO7.6億0.33%2264億 USD0.03%US$80.92-0.27%
Invesco QQQ Trust, Series 1QQQ6.62億0.13%5060.67億 USD0.18%US$746.04-0.70%
Vanguard Morningstar Growth ETFVUG4.47億0.12%3846億 USD0.03%US$91.64-0.36%
iShares Core S&P 500 ETFIVV4.22億0.05%8964.4億 USD0.03%US$781.44-0.07%
State Street SPDR S&P 500 ETFSPY3.84億0.05%8172億 USD0.09%US$778.1-0.06%State Street SPDR S&P 500 ETF1557.TVanguard Morningstar Total Stock Market ETFVTIVanguard S&P 500 ETFVOOVanguard Morningstar Mid-Cap ETFVOInvesco QQQ Trust, Series 1QQQVanguard Morningstar Growth ETFVUGiShares Core S&P 500 ETFIVVState Street SPDR S&P 500 ETFSPYAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
